Moreover, apatinib inhibits the activity of VEGFR, platelet-derived growth factor, c-Kit, and c-Src, which are all tyrosine kinases that are thought to be associated with tumor development.[14] Other studies have indicated that inclusion of apatinib in the treatment regimen could delay the development of resistance to conventional antitumor drugs by inhibiting the activity of ATP-binding cassette transporter subfamily B member 1 and subfamily G member 2.[15,16]. Here, TAP1 is linked to neoplasm.